RNAi Therapeutics Market to hit US$ 8.80 Billion by 2033 | North America leads with 40% share | Major Companies 2026 - Alnylam Pharmaceuticals, Inc, Dicerna Pharmaceuticals, Silence Therapeutics

As per DataM intelligence research report "The Global RNAi Therapeutics Market will grow from USD 2.60 billion in 2024 to USD 8.80 billion by 2033, at a CAGR of 14.6% (2025-2033)"

The market is growing due to advancements in gene-silencing technologies for disease treatment. RNAi therapeutics target specific genes to treat rare and chronic conditions. Increasing investments in biotechnology drive market expansion.

Download your exclusive sample report today: (corporate email gets priority access):
https://www.datamintelligence.com/download-sample/rnai-therapeutics-market?prasad

Technological Advancements

✅ Feb 2026 - AI-Driven RNA Design Enhancing RNAi Therapeutics (Companies: AbbVie, Alnylam Pharmaceuticals)
Advanced AI-integrated platforms are being used to design and optimize siRNA molecules with higher precision and stability. These technologies improve target specificity and accelerate drug discovery timelines across multiple disease areas.

✅ Jan 2026 - Next-Generation siRNA Delivery Using Lipid Nanoparticles (Companies: AbbVie, Silence Therapeutics)
Innovations in lipid nanoparticle (LNP) delivery systems are improving biodistribution and cellular uptake of RNAi therapies. These advancements enable targeted delivery beyond liver tissues, expanding RNAi applications into immunology and fibrosis treatments.

✅ Nov 2025 - Advancements in Gene Silencing Precision for Oncology (Companies: Arrowhead Pharmaceuticals, Takeda Pharmaceutical)
RNAi technologies are evolving to precisely silence disease-causing genes in cancer and rare disorders. Improved siRNA design and conjugation methods are enhancing therapeutic efficacy while reducing off-target effects in clinical pipelines.

Product Launches & Innovations

✅ Dec 2025 - Launch of Dual-Targeting siRNA Therapy for Cardiovascular Diseases (Company: Rona Therapeutics)
Rona Therapeutics introduced a first-in-class bi-valent siRNA candidate targeting PCSK9 and LPA simultaneously. This innovation aims to provide comprehensive lipid reduction and improved cardiovascular risk management in a single therapy.

✅ Mar 2025 - Expansion of RNAi Drug Portfolio with New FDA Approval (Company: Alnylam Pharmaceuticals)
Alnylam expanded its RNAi portfolio with a newly approved therapy targeting rare blood disorders. This milestone highlights growing clinical validation and commercialization of RNA interference as a mainstream therapeutic modality.

✅ Nov 2025 - Pipeline Expansion of RNAi-Based Precision Medicines (Companies: Eli Lilly, Sanegene Bio)
Collaborative programs are accelerating development of RNAi therapies targeting genetic and metabolic diseases. These innovations focus on scalable manufacturing and next-generation precision medicine approaches.

Mergers & Acquisitions

✅ Nov 2025 - Acquisition to Strengthen RNA-Based Therapeutics Portfolio (Company: Novartis)
Novartis acquired Avidity Biosciences to enhance its RNA-targeted therapy capabilities and expand into neuromuscular disorders. The deal integrates advanced antibody-oligonucleotide conjugate technology for improved delivery precision.

✅ Nov 2025 - Strategic Collaborations to Advance RNAi Platforms (Companies: Biovectra, Revolution Biomanufacturing)
Biomanufacturing partnerships are focusing on scaling RNAi production and improving delivery systems. These collaborations aim to accelerate commercialization and ensure supply chain robustness for nucleic acid therapeutics.

✅ Oct 2025 - Expansion Through Acquisition of RNAi-Focused Biotech Firms (Company: Novo Nordisk)
Novo Nordisk strengthened its RNAi pipeline through prior acquisition of Dicerna Pharmaceuticals, enhancing capabilities in liver-targeted gene silencing therapies. This supports long-term expansion into rare and metabolic disease segments.

Rnai therapeutics Market: Competitive Intelligence
Alnylam Pharmaceuticals, Inc, Dicerna Pharmaceuticals, Silence Therapeutics, Arrowhead Pharmaceuticals, Inc, Sanofi, GlaxoSmithKline Plc, Arbutus Biopharma Corporation, Benitec Biopharma, Thermo Fisher Scientific Inc and Sirnaomics, Inc.

Alnylam Pharmaceuticals, Inc., Dicerna Pharmaceuticals, Silence Therapeutics, Arrowhead Pharmaceuticals, Inc., Sanofi, GlaxoSmithKline Plc, Arbutus Biopharma Corporation, Benitec Biopharma, Thermo Fisher Scientific Inc., and Sirnaomics, Inc. are collectively accelerating innovation and clinical progress in the RNAi Therapeutics Market by advancing gene-silencing technologies that enable targeted treatment of complex diseases. These companies are driving the development of RNA interference (RNAi)-based therapies that precisely modulate gene expression, offering new treatment pathways for rare genetic disorders, liver diseases, infectious diseases, and oncology indications. Their investments in delivery platforms, oligonucleotide chemistry, and scalable manufacturing are enhancing therapeutic efficacy, safety, and accessibility. By strengthening clinical pipelines and regulatory engagement, they contribute to the growing validation and commercialization of RNAi-based solutions, reinforcing the expansion of the RNAi Therapeutics Market.

Individually and in combination, these organizations' strengths create competitive differentiation and strong momentum within the RNAi Therapeutics Market by offering complementary expertise across drug discovery, delivery technologies, and biomanufacturing. Alnylam Pharmaceuticals, Inc. and Arrowhead Pharmaceuticals, Inc. lead with advanced RNAi platforms and clinically validated pipelines, while Dicerna Pharmaceuticals and Silence Therapeutics focus on proprietary delivery technologies that improve targeting and durability of gene silencing. Sanofi and GlaxoSmithKline Plc bring global pharmaceutical scale, clinical development expertise, and commercialization capabilities that accelerate market adoption. Arbutus Biopharma Corporation and Benitec Biopharma contribute specialized approaches in antiviral and gene therapy applications, while Sirnaomics, Inc. expands innovation in oncology-focused RNAi therapies. Thermo Fisher Scientific Inc. supports the ecosystem with critical manufacturing, analytical, and research solutions, enabling efficient development and scale-up. This integrated value chain strengthens innovation and adoption across the RNAi Therapeutics Market.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/rnai-therapeutics-market?prasad

Segment Covered in the Rnai therapeutics Market:
By Type
The market is segmented into small interfering RNAs (siRNA) 65% and microRNA (miRNA) 35%, with siRNA dominating due to its high specificity, strong gene-silencing efficiency, and increasing number of approved and pipeline therapies. miRNA is gaining traction in advanced research applications due to its ability to regulate multiple genes simultaneously. Growing investment in gene therapy and precision medicine supports segment growth.

By Application
Applications include oncology 30%, cardiovascular 10%, respiratory disorders 10%, renal diseases 10%, genetic disorders 15%, neurodegenerative disorders 10%, infectious diseases 10%, and others 5%, with oncology leading due to rising cancer prevalence and strong pipeline of RNAi-based therapeutics. Genetic and neurodegenerative disorders are emerging areas with significant growth potential. Increasing focus on targeted therapies and rare disease treatment drives adoption.

By Route of Administration
Routes of administration include intravenous injections 50%, pulmonary delivery 20%, intradermal injections 10%, intraperitoneal injections 10%, and others 10%, with intravenous injections dominating due to efficient systemic delivery and widespread clinical use. Pulmonary delivery is gaining attention for respiratory diseases. Advancements in drug delivery technologies enhance therapeutic effectiveness and patient compliance.

By End-User
End-users include hospitals 50%, research and academic laboratories 30%, and diagnostic laboratories 20%, with hospitals leading due to increasing use of RNAi therapeutics in clinical treatments and trials. Research and academic laboratories play a key role in drug development and innovation. Diagnostic laboratories support disease identification and monitoring. Rising R&D investments and clinical trial activities drive segment growth.

Buy Now & Unlock 360° Market Intelligence:
https://www.datamintelligence.com/buy-now-page?report=rnai-therapeutics-market

Regional Analysis
North America - 40% Share
North America leads with 40% share driven by strong presence of key biotech companies such as Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Arrowhead Pharmaceuticals. High investment in research, advanced healthcare infrastructure, and early adoption of innovative therapies support growth. Oncology and genetic disorder applications dominate.

Europe - 25% Share
Europe holds 25% share with significant contributions from countries like Germany, France, and the United Kingdom. Increasing clinical trials and government support for biotechnology drive market growth. Oncology and cardiovascular applications are prominent. Strong academic research ecosystem supports innovation.

Asia Pacific - 20% Share
Asia Pacific accounts for 20% share driven by rapid growth in biotechnology sectors in China, Japan, and India. Increasing healthcare investments and rising awareness of advanced therapies support adoption. Genetic and infectious disease applications are growing significantly.

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?prasad

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.